A detailed history of Values First Advisors, Inc. transactions in Guardant Health, Inc. stock. As of the latest transaction made, Values First Advisors, Inc. holds 32,025 shares of GH stock, worth $1.1 Million. This represents 0.4% of its overall portfolio holdings.

Number of Shares
32,025
Previous 28,248 13.37%
Holding current value
$1.1 Million
Previous $815,000 9.94%
% of portfolio
0.4%
Previous 0.49%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$22.3 - $36.29 $84,227 - $137,067
3,777 Added 13.37%
32,025 $734,000
Q2 2024

Jul 19, 2024

SELL
$16.07 - $31.84 $126,358 - $250,357
-7,863 Reduced 21.77%
28,248 $815,000
Q1 2024

Apr 23, 2024

BUY
$17.13 - $26.91 $16,718 - $26,264
976 Added 2.78%
36,111 $744,000
Q4 2023

Jan 18, 2024

BUY
$21.58 - $29.5 $99,354 - $135,818
4,604 Added 15.08%
35,135 $950,000
Q3 2023

Nov 08, 2023

SELL
$25.8 - $39.97 $312,618 - $484,316
-12,117 Reduced 28.41%
30,531 $904,000
Q2 2023

Aug 02, 2023

BUY
$20.94 - $38.01 $204,479 - $371,167
9,765 Added 29.7%
42,648 $1.53 Million
Q1 2023

May 15, 2023

BUY
$22.92 - $33.76 $439,238 - $646,976
19,164 Added 139.69%
32,883 $770,000
Q4 2022

Jan 20, 2023

SELL
$25.44 - $59.78 $71,181 - $167,264
-2,798 Reduced 16.94%
13,719 $0
Q3 2022

Dec 02, 2022

BUY
$43.66 - $61.0 $2,619 - $3,660
60 Added 0.36%
16,517 $889,000
Q2 2022

Jul 20, 2022

BUY
$28.82 - $77.35 $217,792 - $584,533
7,557 Added 84.91%
16,457 $664,000
Q1 2022

May 03, 2022

BUY
$48.25 - $100.49 $262,383 - $546,464
5,438 Added 157.08%
8,900 $590,000
Q4 2021

Mar 10, 2022

BUY
$88.71 - $120.43 $307,114 - $416,928
3,462 New
3,462 $346,000

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $3.51B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Values First Advisors, Inc. Portfolio

Follow Values First Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Values First Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Values First Advisors, Inc. with notifications on news.